solute carrier family 25 member 5Genealiases: 2F1 · AAC2 · ANT2 · T2 · T3
Q-omics provides the consensus-scored SLC25A5 profile across patient tissues and cancer cell-line models. SLC25A5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, SLC25A5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SLC25A5 protein abundance shows 30,963 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ESCA, KIRC, and LSCC as cancer lineages where SLC25A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A5 survival associations across molecular data types. SLC25A5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A5 RNA expression–survival associations across cancer types. High SLC25A5 expression shows unfavorable associations in ESCA, BRCA, UVM, HNSC and LIHC, but favorable associations in KIRC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for SLC25A5 RNA expression.
This table summarizes SLC25A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A5 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LIHC, HNSC, UCEC and BRCA. The KIRC box plot shows higher SLC25A5 RNA expression in normal versus tumor tissue (log2 FC = −1.392, t-test p < 0.001).
This table shows molecular features associated with SLC25A5 in patient tissues and cancer cell lines. In patient samples, SLC25A5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
